Prolia, a medication used to treat osteoporosis and other bone density conditions, can cause a range of side effects. Common adverse events include pain in the limbs, muscle pain, and abdominal pain. Some individuals may experience urinary tract infections and pneumonia [1].
What other side effects have been reported with Prolia?
More serious side effects associated with Prolia include serious infections. Decreases in calcium levels (hypocalcemia) can occur, which can be severe. Osteonecrosis of the jaw (ONJ), a condition where the jawbone does not heal after injury or surgery, has been reported in patients taking Prolia [1]. Severe allergic reactions are also possible [2].
How does Prolia work to treat osteoporosis?
Prolia works by inhibiting the activity of osteoclasts, a type of cell responsible for breaking down bone. By reducing bone resorption, Prolia helps to increase bone mineral density and reduce the risk of fractures [3].
Are there alternatives to Prolia for osteoporosis?
Yes, several alternative treatments exist for osteoporosis, including other medications that target bone resorption or bone formation. Bisphosphonates (like alendronate, risedronate, and zoledronic acid) and denosumab (the active ingredient in Prolia) are common treatment options. Other classes of drugs include hormone-related therapies and anabolic agents [4].
What is the patent status of Prolia?
The U.S. patent for Prolia, denosumab, is set to expire in December 2025. However, there are multiple other patents covering the drug, some of which extend beyond this date [5]. This complex patent landscape can affect the timeline for generic or biosimilar competition.
When might biosimilars of Prolia become available?
The availability of biosimilars for Prolia depends on patent expirations and any ongoing litigation. While the primary patent expires in 2025, other related patents could create further barriers to entry for biosimilar manufacturers [5]. DrugPatentWatch.com tracks these developments.